PuSH - Publication Server of Helmholtz Zentrum München

Wesolowska-Andersen, A.* ; Brorsson, C.A.* ; Bizzotto, R.* ; Mari, A.* ; Tura, A.* ; Koivula, R.W.* ; Mahajan, A.* ; Viñuela, A.* ; Tajes, J.F.* ; Sharma, S. ; Haid, M. ; Prehn, C. ; Artati, A. ; Hong, M.G.* ; Musholt, P.B.* ; Kurbasic, A.* ; De Masi, F.* ; Tsirigos, K.D.* ; Pedersen, H.K.* ; Gudmundsdottir, V.* ; Thomas, C.E.* ; Banasik, K.* ; Jennison, C.* ; Jones, A.* ; Kennedy, G.* ; Bell, J.* ; Thomas, L.* ; Frost, G.* ; Thomsen, H.* ; Allin, K.* ; Hansen, T.H.* ; Vestergaard, H.* ; Hansen, T.* ; Rutters, F.* ; Elders, P.* ; t'Hart, L.* ; Bonnefond, A.* ; Canouil, M.* ; Brage, S.* ; Kokkola, T.* ; Heggie, A.* ; McEvoy, D.* ; Hattersley, A.* ; McDonald, T.A.* ; Teare, H.* ; Ridderstråle, M.* ; Walker, M.* ; Forgie, I.* ; Giordano, G.N.* ; Froguel, P.* ; Pavo, I.* ; Ruetten, H.* ; Pedersen, O.* ; Dermitzakis, E.* ; Franks, P.W.* ; Schwenk, J.M.* ; Adamski, J. ; Pearson, E.* ; McCarthy, M.I.* ; Brunak, S.*

Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study.

Cell Rep. Med. 3:100477 (2022)
Postprint Research data DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The presentation and underlying pathophysiology of type 2 diabetes (T2D) is complex and heterogeneous. Recent studies attempted to stratify T2D into distinct subgroups using data-driven approaches, but their clinical utility may be limited if categorical representations of complex phenotypes are suboptimal. We apply a soft-clustering (archetype) method to characterize newly diagnosed T2D based on 32 clinical variables. We assign quantitative clustering scores for individuals and investigate the associations with glycemic deterioration, genetic risk scores, circulating omics biomarkers, and phenotypic stability over 36 months. Four archetype profiles represent dysfunction patterns across combinations of T2D etiological processes and correlate with multiple circulating biomarkers. One archetype associated with obesity, insulin resistance, dyslipidemia, and impaired β cell glucose sensitivity corresponds with the fastest disease progression and highest demand for anti-diabetic treatment. We demonstrate that clinical heterogeneity in T2D can be mapped to heterogeneity in individual etiological processes, providing a potential route to personalized treatments.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
16.988
0.000
19
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Archetypes ; Disease Progression ; Glycaemic Deterioration ; Multi-omics ; Patient Clustering ; Patient Stratification ; Precision Medicine ; Soft-clustering ; Type 2 Diabetes; Genome-wide Association; Insulin-resistance; Cell Dysfunction; Fat-content; Onset; Normalization; Mechanisms; Generation; Subgroups; Atlas
Language english
Publication Year 2022
HGF-reported in Year 2022
ISSN (print) / ISBN 2666-3791
e-ISSN 2666-3791
Quellenangaben Volume: 3, Issue: 1, Pages: , Article Number: 100477 Supplement: ,
Publisher Cell Press
Publishing Place Radarweg 29, 1043 Nx Amsterdam, Netherlands
Reviewing status Peer reviewed
Institute(s) Molekulare Endokrinologie und Metabolismus (MEM)
CF Metabolomics & Proteomics (CF-MPC)
Institute of Experimental Genetics (IEG)
POF-Topic(s) 30201 - Metabolic Health
30505 - New Technologies for Biomedical Discoveries
Research field(s) Genetics and Epidemiology
Enabling and Novel Technologies
PSP Element(s) G-505600-003
A-630710-001
G-500600-001
Grants Innovative Medicines Initiative 2 Joint Undertaking
European Union
Novo Nordisk Foundation
Wellcome Trust New Investigator Award
NIDDK
Wellcome Trust
Innovative Medicines Initiative Joint Undertaking
Scopus ID 85122950661
PubMed ID 35106505
Erfassungsdatum 2022-06-08